These therapies have demonstrated success in preclinical models for other ALS subtypes, like SOD1 and C9orf72, and efforts to develop similar approaches for VAPB-related ALS8 are in the early stages [5,32]. The gene discussed is VAPB; the disease is amyotrophic lateral sclerosis type 8.